Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Melanin + Phenytoin + Sirolimus + SM88 |
| Synonyms | SMK |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Melanin | ||||
| Phenytoin | Aleviatin | 5,5-Dwufenylohydantoina | ||
| SM88 | SM-88|Racemetyrosine|Racemetirosine | SM88 is a modified tyrosine derivative that may interfere with protein synthesis, leading to oxidative damage and cell death in tumor cells (PMID: 31358523, PMID: 30929156). | ||
| Sirolimus | Rapamune | Rapamycin | mTORC1 Inhibitor 9 | Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|